Synthesis and Cytotoxicity of Octahydroepoxyisoindole-7-carboxylic Acids and Norcantharidin-Amide Hybrids as Norcantharidin Analogues.


Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
18 06 2019
Historique:
received: 19 03 2019
pubmed: 3 4 2019
medline: 18 4 2020
entrez: 3 4 2019
Statut: ppublish

Résumé

Octahydroepoxyisoindole analogues of norcantharidin were accessed through a Diels-Alder reaction of an amine-substituted furan with maleic anhydride and subsequent reduction of the bicyclo[2.2.1]heptene olefin. Despite retention of the carboxylate and the ether bridgehead known to impart cytotoxic activity to norcantharidin, none of these analogues displayed notable cytotoxicity against the 11 cell lines examined: HT29 (colon), MCF-7 (breast), A2780 (ovarian), H460 (lung), A431 (skin), Du145 (prostate), BE2-C (neuroblastoma), SJ-G2 and U87 (glioblastoma), MIA (pancreatic), and SMA (spontaneous murine astrocytoma). The incorporation of an amino-substituted system post-synthesis of norcantharidin afforded facile access to 14 acid/amide-substituted norcantharidin analogues. Of these, only four displayed sufficient activity at the initial 25 μm compound screening dose to warrant full evaluation of growth inhibition. Common to these analogues was the presence of a 4-biphenyl moiety, and in particular 3-(2-(furan-2-ylmethyl)-3-(4-biphenylamino)-3-oxopropylcarbamoyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid (13 c) and 3-(2-(pyrrole-2-ylmethyl)-3-(4-biphenylamino)-3-oxopropylcarbamoyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid (24) displayed high levels of cytotoxicity, returning GI

Identifiants

pubmed: 30938091
doi: 10.1002/cmdc.201900180
doi:

Substances chimiques

Amides 0
Antineoplastic Agents 0
Bridged Bicyclo Compounds, Heterocyclic 0
Isoindoles 0
norcantharidin 8452E71EO7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1152-1161

Informations de copyright

© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Auteurs

Lacey Hizartzidis (L)

Chemistry, School of Environmental & Life Sciences, The University of Newcastle, 1 University Drive, Callaghan, NSW, 2308, Australia.

Jayne Gilbert (J)

Experimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Hospital, Edith Street, Waratah, NSW, 2298, Australia.

Christopher P Gordon (CP)

Chemistry, School of Environmental & Life Sciences, The University of Newcastle, 1 University Drive, Callaghan, NSW, 2308, Australia.
Present address: Department: School of Science and Health, Western Sydney University, Locked Bag 1797, Penrith South DC, NSW, 2750, Australia.

Jennette A Sakoff (JA)

Experimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Hospital, Edith Street, Waratah, NSW, 2298, Australia.

Adam McCluskey (A)

Chemistry, School of Environmental & Life Sciences, The University of Newcastle, 1 University Drive, Callaghan, NSW, 2308, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH